FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160753417> ?p ?o ?g. }

• W3160753417 endingPage "256" @default.
• W3160753417 startingPage "244" @default.
• W3160753417 abstract "Immune checkpoint blockade treatment is one of the most promising immunotherapies, which exhibits promising therapeutic effects on inhibition of metastasis. However, immunotherapy has little effect on pancreatic cancer, due to its extensive fibrotic matrix and immunosuppressive tumor microenvironment. Mild hyperthermia induced by photothermal therapy (PTT) has been proven to activate the immune responses in the tumor microenvironment. Herein, we designed a combine strategy of mild hyperthermia and immune checkpoint blockade (BMS-202) treatment with size-adjustable thermo- and fibrotic matrix- sensitive liposomes (HSA-BMS@CAP-ILTSL), in which BMS-202 loaded small-sized albumin nanoparticle (HSA-BMS) was encapsulated. Mild hyperthermia reduced the tumor hypoxia, relieved the interstitial pressure and increased the recruitment of endogenous immune cells in tumors. In the meantime, small-sized HSA-BMS was released from large-sized HSA-BMS@CAP-ILTSL in response to fibroblast activation protein-α (FAP-α) and near-infrared (NIR) laser, and enhanced the immunological responses by recovering the activity of T lymphocytes, accompanied by secreting relevant cytokines (TNF-α and IFN-γ). The combined therapy (HSA-BMS@CAP-ILTSL) could not only significantly suppress the tumor growth in vivo, but also decrease the amounts of metastatic nodules in distant organs. These results suggested that size-adjustable nanoparticles had a great potential in the treatment of metastatic pancreatic cancer. STATEMENT OF SIGNIFICANCE: The desmoplastic stroma and hypoperfusion of pancreatic cancer imposed physical barriers to effective therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy. We constructed size-adjustable thermo- and fibrotic matrix- sensitive liposomes (HSA-BMS@CAP-ILTSL) with size around 120 nm, where small sized albumin nanoparticle (10 nm) of immune checkpoint inhibitor (HSA-BMS) were encapsulated inside. Mild hyperthermia not only contributed to release HSA-BMS for penetration (blocking the immunosuppressive signals deep in the tumor), but enhanced tumor blood perfusion for infiltration of endogenous immune cells. In the two-pronged treatment, the pancreatic cancer immunotherapy significantly enhanced and the risk of cancer metastasis was reduced. Overall, the strategy provides a promising approach to increase drug accumulation and improve the anti-tumor immune activity in pancreatic cancer." @default.
• W3160753417 created "2021-05-24" @default.
• W3160753417 creator A5001421484 @default.
• W3160753417 creator A5002083216 @default.
• W3160753417 creator A5010323969 @default.
• W3160753417 creator A5021803196 @default.
• W3160753417 creator A5026174200 @default.
• W3160753417 creator A5032276597 @default.
• W3160753417 creator A5032767831 @default.
• W3160753417 creator A5043450678 @default.
• W3160753417 creator A5053985637 @default.
• W3160753417 creator A5055427794 @default.
• W3160753417 creator A5065502386 @default.
• W3160753417 creator A5070324904 @default.
• W3160753417 creator A5077838779 @default.
• W3160753417 date "2021-10-01" @default.
• W3160753417 modified "2023-10-15" @default.
• W3160753417 title "Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles" @default.
• W3160753417 cites W1173721300 @default.
• W3160753417 cites W1968583232 @default.
• W3160753417 cites W2000568918 @default.
• W3160753417 cites W2030173263 @default.
• W3160753417 cites W2060420887 @default.
• W3160753417 cites W206644305 @default.
• W3160753417 cites W2075093379 @default.
• W3160753417 cites W2131052485 @default.
• W3160753417 cites W2347141054 @default.
• W3160753417 cites W2409322723 @default.
• W3160753417 cites W2533513686 @default.
• W3160753417 cites W2555883270 @default.
• W3160753417 cites W2579046240 @default.
• W3160753417 cites W2659075027 @default.
• W3160753417 cites W2734489076 @default.
• W3160753417 cites W2738949321 @default.
• W3160753417 cites W2740931940 @default.
• W3160753417 cites W2744383407 @default.
• W3160753417 cites W2746888048 @default.
• W3160753417 cites W2781748744 @default.
• W3160753417 cites W2801862810 @default.
• W3160753417 cites W2897780306 @default.
• W3160753417 cites W2907532738 @default.
• W3160753417 cites W2909528400 @default.
• W3160753417 cites W2911909558 @default.
• W3160753417 cites W2913836031 @default.
• W3160753417 cites W2921773418 @default.
• W3160753417 cites W2951862601 @default.
• W3160753417 cites W2977511465 @default.
• W3160753417 cites W2981954871 @default.
• W3160753417 cites W2995819326 @default.
• W3160753417 cites W3009937214 @default.
• W3160753417 cites W3023887961 @default.
• W3160753417 cites W3023933939 @default.
• W3160753417 cites W3039693333 @default.
• W3160753417 cites W3039726497 @default.
• W3160753417 doi "https://doi.org/10.1016/j.actbio.2021.05.002" @default.
• W3160753417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34000465" @default.
• W3160753417 hasPublicationYear "2021" @default.
• W3160753417 type Work @default.
• W3160753417 sameAs 3160753417 @default.
• W3160753417 citedByCount "40" @default.
• W3160753417 countsByYear W31607534172021 @default.
• W3160753417 countsByYear W31607534172022 @default.
• W3160753417 countsByYear W31607534172023 @default.
• W3160753417 crossrefType "journal-article" @default.
• W3160753417 hasAuthorship W3160753417A5001421484 @default.
• W3160753417 hasAuthorship W3160753417A5002083216 @default.
• W3160753417 hasAuthorship W3160753417A5010323969 @default.
• W3160753417 hasAuthorship W3160753417A5021803196 @default.
• W3160753417 hasAuthorship W3160753417A5026174200 @default.
• W3160753417 hasAuthorship W3160753417A5032276597 @default.
• W3160753417 hasAuthorship W3160753417A5032767831 @default.
• W3160753417 hasAuthorship W3160753417A5043450678 @default.
• W3160753417 hasAuthorship W3160753417A5053985637 @default.
• W3160753417 hasAuthorship W3160753417A5055427794 @default.
• W3160753417 hasAuthorship W3160753417A5065502386 @default.
• W3160753417 hasAuthorship W3160753417A5070324904 @default.
• W3160753417 hasAuthorship W3160753417A5077838779 @default.
• W3160753417 hasConcept C121608353 @default.
• W3160753417 hasConcept C126322002 @default.
• W3160753417 hasConcept C170493617 @default.
• W3160753417 hasConcept C192562407 @default.
• W3160753417 hasConcept C203014093 @default.
• W3160753417 hasConcept C2776107976 @default.
• W3160753417 hasConcept C2777701055 @default.
• W3160753417 hasConcept C2778468042 @default.
• W3160753417 hasConcept C2779949491 @default.
• W3160753417 hasConcept C2780210213 @default.
• W3160753417 hasConcept C2780851360 @default.
• W3160753417 hasConcept C2781274730 @default.
• W3160753417 hasConcept C502942594 @default.
• W3160753417 hasConcept C71924100 @default.
• W3160753417 hasConcept C8891405 @default.
• W3160753417 hasConceptScore W3160753417C121608353 @default.
• W3160753417 hasConceptScore W3160753417C126322002 @default.
• W3160753417 hasConceptScore W3160753417C170493617 @default.
• W3160753417 hasConceptScore W3160753417C192562407 @default.
• W3160753417 hasConceptScore W3160753417C203014093 @default.
• W3160753417 hasConceptScore W3160753417C2776107976 @default.

• next